文献速递核素与放射性配体治疗肿瘤 PET/CT

低瘤负荷激素敏感性转移性前列腺癌患者[177Lu]Lu-PSMA-617治疗内剂量学及与疗效的相关性

Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-07-04

结果显示mHSPC患者[177Lu]Lu-PSMA药代动力学与mCRPC患者相当,病灶吸收剂量高(3.25±3.19 Gy/GBq),显著高于唾液腺(0.39±0.17 Gy/GBq)、肾脏(0.49±0.11 Gy/GBq)、肝脏(0.09±0.01 Gy/GBq)和骨髓(0.017±0.008 Gy/GBq)。治疗反应与指标病灶吸收剂量间存在统计学显著相关(p=0.047)。

要点

  • mHSPC患者[177Lu]Lu-PSMA药代动力学与mCRPC患者相当
  • 病灶吸收剂量(3.25±3.19 Gy/GBq)远高于危及器官
  • 治疗反应与指标病灶吸收剂量显著相关(p=0.047)

核心结论

  • 成功实施小病灶剂量学测定,mHSPC患者的肿瘤汇效应担忧低于预期。
  • 肿瘤与器官吸收剂量比值高,肿瘤摄取与PSA反应相关。
  • 就器官毒性而言,追加治疗周期是合理的,可能带来更好的肿瘤反应。

研究设计与样本

  • 每例患者接受两周期[177Lu]Lu-PSMA治疗。
  • 每次治疗后5个时间点行三床位SPECT/CT显像。
  • 器官剂量学采用商业软件分析,病灶剂量学采用手动方法分析。

主要发现

  • mHSPC患者[177Lu]Lu-PSMA药代动力学与mCRPC患者相当。
  • 病灶吸收剂量为3.25±3.19 Gy/GBq。
  • 唾液腺吸收剂量为0.39±0.17 Gy/GBq,肾脏为0.49±0.11 Gy/GBq。
  • 肝脏吸收剂量为0.09±0.01 Gy/GBq,骨髓为0.017±0.008 Gy/GBq。
  • 治疗反应(研究结束时PSA下降>50%)与指标病灶吸收剂量间存在统计学显著相关(p=0.047)。

关键数值与推荐

  • 肿瘤病灶直径<1 cm者纳入病灶剂量学分析。
  • 治疗反应定义为研究结束时PSA下降>50%。
  • 相关性以Spearman's r和p值表示,指标病灶吸收剂量与治疗反应相关p=0.047。

临床怎么用

  • mHSPC患者可考虑[177Lu]Lu-PSMA治疗,小病灶剂量学可行。
  • 肿瘤汇效应在低瘤负荷mHSPC中担忧程度低于预期,可关注追加治疗周期的合理性。

局限性

  • 病灶剂量学采用手动方法,可能存在操作者依赖性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: While [177Lu]Lu-PSMA radioligand therapy is currently only applied in end-stage metastatic castrate-resistant prostate cancer (mCRPC) patients, also low-volume hormone-sensitive metastatic prostate cancer (mHSPC) patients can benefit from it. However, there are toxicity concerns related to the sink effect in low-volume disease. This prospective study aims to determine the kinetics of [177Lu]Lu-PSMA in mHSPC patients, analyzing the doses to organs at risk (salivary glands, kidneys, liver, and bone marrow) and tumor lesions < 1 cm diameter. METHODS: Ten mHSPC patients underwent two cycles of [177Lu]Lu-PSMA therapy. Three-bed position SPECT/CT was performed at 5 time points after each therapy. Organ dosimetry and lesion dosimetry were performed using commercial software and a manual approach, respectively. Correlation between absorbed index lesion dose and treatment response (PSA drop of > 50% at the end of the study) was calculated and given as Spearman's r and p-values. RESULTS: Kinetics of [177Lu]Lu-PSMA in mHSPC patients are comparable to those in mCRPC patients. Lesion absorbed dose was high (3.25 ± 3.19 Gy/GBq) compared to organ absorbed dose (salivary glands: 0.39 ± 0.17 Gy/GBq, kidneys: 0.49 ± 0.11 Gy/GBq, liver: 0.09 ± 0.01 Gy/GBq, bone marrow: 0.017 ± 0.008 Gy/GBq). A statistically significant correlation was found between treatment response and absorbed index lesion dose (p = 0.047). CONCLUSIONS: We successfully performed small lesion dosimetry and showed that the tumor sink effect in mHSPC patients is of less concern than was expected. Tumor-to-organ ratio of absorbed dose was high and tumor uptake correlates with PSA response. Additional treatment cycles are legitimate in terms of organ toxicity and could lead to better tumor response.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Peters SMB, Privé BM, de Bakker M, et al. Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. Eur J Nucl Med Mol Imaging. 2021. PMID: 34218300. doi:10.1007/s00259-021-05471-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。